Psychedelic drugs like psilocybin, LSD and MDMA have amazing medicinal and commercial potential. So does ketamine, but ketamine is already legal.
Psychedelic drugs like psilocybin, LSD and MDMA have amazing medicinal and commercial potential. So does ketamine, but ketamine is already legal.
The Schedule I classification for psychedelic drugs needs to be changed. But to what -- and when? Psychedelic Stock Watch takes a broad look at that question.
Two billion people suffer from treatable mental health disorders resulting in 8 million preventable deaths per year. Psychedelics can address this catastrophe -- but first these drugs must be legalized.
Recent market clues are suggesting that a much overdue rally for psychedelic stocks may be about to begin.
Psychedelic medicine is the solution to the Mental Health Crisis. Psychedelic drugs are a huge commercial opportunity. Big Business moves in.
We take a closer look at each of the three psychedelics ETFs and analyze the investment objectives that each ETF addresses.
Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.
Big Pharma's business model for drug development is all about maximizing profits, not health. Psychedelic medicine can maximize profits AND health.
Two BILLION people with untreated mental health disorders is a lot of market potential. We attach some numbers to these treatment markets.
Roughly 8 million people per year are dying preventable deaths because of lack of (legal) access to psychedelic medicine. It's also killing the economy.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now